NCT06741072 2026-01-08
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
Ohio State University Comprehensive Cancer Center
Phase 1 Suspended
Clinical Trials
9 trialsNCT00001572 2017-07-02
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00003224 2014-11-20
Vaccine Therapy in Treating Patients With Metastatic Melanoma
University of Virginia
Phase 1 Completed
NCT00006387 2013-07-11
Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer
Fox Chase Cancer Center
Phase 1 Completed
NCT00006041 2013-06-19
Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00036933 2013-03-25
Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00003819 2013-03-19
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00004929 2013-01-31
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00003357 2012-12-13
Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease
Memorial Sloan Kettering Cancer Center
Phase 1 Completed